血清鳞状细胞癌抗原检测在宫颈鳞癌患者中的临床应用

Serum SCC-Ag level and its clinical value in the carcinoma of the uterine cervix

目的探讨血清鳞状细胞癌抗原(SCC-Ag)对监测宫颈癌病情程度、治疗效果及复发的临床价值。方法使用全自动快速荧光酶标分析仪系统(IMX)测定135例宫颈鳞癌患者血清SCC-Ag水平。结果宫颈原位癌与浸润癌SCC阳性率分别为5.6%和46.9%。宫颈浸润癌Ⅰ期、Ⅱ期、Ⅲ期SCC阳性率分别为12.9%、82.6%、92.3%。26例肿瘤直径≥4 cm患者血清SCC-Ag中位值为8.2 ng/m l,55例肿瘤直径<4 cm的患者血清SCC-Ag中位值为3.2 ng/m l。淋巴结转移24例,15例血清SCC阳性,阳性率为62.5%,血清SCC-Ag中位值为9.2 ng/m l;无淋巴结转移40例,12例血清SCC阳性,阳性率为30.0%,血清SCC-Ag中位数值为3.6 ng/m l。结论血清SCC-Ag是宫颈鳞癌较特异的肿瘤标志物,对宫颈癌诊断及治疗方案的选择有重要的参考价值。

Objective To investigate the clinical usefulness of the serum squamous cell carcinoma antigen（SCC） in staging, monitoring of therapy and detection of recurrence of squamous cell carcinoma of the cervix. Methods The SCC serum levels of 135 patients were determined using microparticle enzyme immunoassay（IMX）. Results Increased levels of SCC were found in 5.6% and 46.9% of the patients with carcinoma in situ and invasive carcinoma of the uterine cervix respectively. Elevated SCC levels were found in 12.9% of the cases with stage- Ⅰ , 82.6% of stage- Ⅱ and 92.3% of stage-Ⅲ cervical invasive carcinoma. The median SCC serum levels were 8.2 ng/ml in 26 cases with tumor size ≥4 cm and 3.2 ng/ml in 55 cases with tumor size 〈4 cm. There were 15 patients with SCC positive in 24 lymph node-positive cases and the median SCC level was 9.2 ng/ml. There were 12 patients with SCC positive in 40 lymph node-negative cases and the median SCC level was 3.6 ng/ml. Conclusion SCC-Ag is a specific tumor marker of the squamous cell carcinoma of cervix, and is useful for diagnosis and treatment of the squamous cell carcinoma of cervix.